The estimated Net Worth of George Golumbeski is at least $2.9 Million dollars as of 5 May 2022. George Golumbeski owns over 8,000 units of Sage Therapeutics Inc stock worth over $59,920 and over the last 11 years he sold SAGE stock worth over $0. In addition, he makes $2,843,390 as Independent Director at Sage Therapeutics Inc.
Sign up
George Golumbeski SAGE stock SEC Form 4 insiders trading
George has made over 5 trades of the Sage Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 8,000 units of SAGE stock worth $251,600 on 5 May 2022.
The largest trade he's ever made was buying 28,330 units of Sage Therapeutics Inc stock on 26 April 2022 worth over $102,838. On average, George trades about 2,846 units every 39 days since 2014. As of 5 May 2022 he still owns at least 8,000 units of Sage Therapeutics Inc stock.
You can see the complete history of George Golumbeski stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
George Golumbeski biography
Dr. George S. Golumbeski Ph.D. serves as Independent Director of the Company. Dr. Golumbeski previously served as the President of GRAIL, Inc., a health-care company focused on the early detection of cancer. From 2009 to 2018, Dr. Golumbeski was employed by Celgene Corporation, or Celgene, where he led all business development activities including in-licensing, mergers and acquisitions, and alliance management. Prior to Celgene, Dr. Golumbeski was Vice President of Business Development, Licensing, and Strategy at Novartis. Earlier in his career, he held leadership positions at Elan Pharmaceuticals Inc. and Schwarz Pharma AG, where he focused on neurology and neuropsychiatry therapeutics. Additionally, in the past five years, Dr. Golumbeski has served on the board of directors of Aura Biosciences, Inc., Carrick Therapeutics, KSQ Therapeutics, Inc., Shattuck Labs, Inc., Verseau Therapeutics, Inc., Enanta Pharmaceuticals, Inc. and MorphoSys AG. Dr. Golumbeski received a B.A. in Biology from the University of Virginia and a Ph.D. in Genetics from the University of Wisconsin—Madison. Golumbeski’s qualifications to sit on our Board of Directors include his years of experience in research and development, business development transactions and leadership at various pharmaceutical companies.
What is the salary of George Golumbeski?
As the Independent Director of Sage Therapeutics Inc, the total compensation of George Golumbeski at Sage Therapeutics Inc is $2,843,390. There are 7 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.
What's George Golumbeski's mailing address?
George's mailing address filed with the SEC is C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN, TX, 78701.
Insiders trading at Sage Therapeutics Inc
Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen und Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.
What does Sage Therapeutics Inc do?
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
What does Sage Therapeutics Inc's logo look like?
Complete history of George Golumbeski stock trades at Corbus Pharmaceuticals Inc, Enanta Pharmaceuticals Inc, Sage Therapeutics Inc und Shattuck Labs
Sage Therapeutics Inc executives and stock owners
Sage Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jeffrey Jonas,
President, Chief Executive Officer and Director -
Michael Cloonan,
Chief Operating Officer -
Stephen Kanes,
Chief Medical Officer -
Anne Cook,
Senior Vice President, General Counsel, Secretary -
Kimi Iguchi,
Chief Financial Officer, Treasurer -
Albert Robichaud,
Chief Scientific Officer -
Elizabeth Barrett,
Independent Director -
George Golumbeski,
Independent Director -
Dr. Jeffrey M. Jonas,
Chief Innovation Officer, Chair of the Science & Technology Forum and Director -
Kevin Starr,
Independent Chairman of the Board -
Michael Cola,
Independent Director -
James Frates,
Independent Director -
Steven Paul,
Independent Director -
Geno Germano,
Independent Director -
Asha Nayak,
Independent Director -
Anne Marie Cook,
Sr. VP, Gen. Counsel & Sec. -
Dr. Albert J. Robichaud Ph.D.,
Chief Scientific Officer -
Kimi E. Iguchi,
CFO & Treasurer -
Barry E. Greene,
Pres, CEO & Director -
Barry Greene,
Director -
Dr. Jim Doherty Ph.D.,
Chief Devel. Officer -
Dr. Amy Schacterle Ph.D.,
Sr. VP of R&D Strategy and Bus. Management -
Erin E. Lanciani,
Chief People & Experience Officer -
Helen Rubinstein,
Investor Relations Officer -
Matt Lasmanis,
Chief Technology & Innovation Officer -
Rock Ventures Ii, L.P.Third...,
-
Howard H Pien,
-
Thomas Anderson,
See Remarks -
Robert Nelsen,
Director -
Venture Fund Vii Lparch Ven...,
-
Rock Ventures Ii, L.P.Third...,
-
Laura Gault,
Chief Medical Officer -
Jessica Federer,
-
Christopher Benecchi,
Chief Business Officer